Evidence map›Paper›PMID 41718015›Full record

ArticleAndrology2026

Microfluidic Intracytoplasmic Sperm Injection (MICSI): A Novel Platform for Sperm Isolation, Selection, and Injection Into Oocytes.

Mehran Dabiri, Dale Mark Goss, Steven Alexander Vasilescu, Majid Ebrahimi Warkiani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Andrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mehran DabiriSchool of Biomedical Engineering, Faculty of Engineering and IT, University of Technology Sydney, Sydney, New South Wales, Australia.
Dale Mark GossSchool of Biomedical Engineering, Faculty of Engineering and IT, University of Technology Sydney, Sydney, New South Wales, Australia.
Steven Alexander VasilescuSchool of Biomedical Engineering, Faculty of Engineering and IT, University of Technology Sydney, Sydney, New South Wales, Australia.
Majid Ebrahimi WarkianiSchool of Biomedical Engineering, Faculty of Engineering and IT, University of Technology Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-4184-1944

Funding

Cancer Institute New South WalesNational Collaborative Research Infrastructure Strategy
6 · The paper itself

Abstract

backgroundInfertility is a pressing global health concern, affecting one in six couples worldwide. The failure rate for assisted reproductive technologies (ART) cycles remains at approximately 78%, with limited improvements often attributed to a lack of technological innovation. Sperm processing, a crucial component of ART success and offspring health, has seen minimal technical advancement, and current "gold-standard" methods such as density gradient centrifugation (DGC) carry risks of iatrogenic injury and DNA damage.

objectivesMicrofluidic sperm selection technologies have shown promise in leveraging sperm's unique motility behaviors by mimicking the female reproductive tract's microarchitecture.

methodsIn this study, we introduce a microfluidic ICSI (MICSI) platform by integrating microfluidic technology into the form factor of commercially available ICSI dishes, to integrate semen processing, motility and hyaluronic acid (HA) binding-based sperm selection, and oocyte insemination capacity on one single-use consumable. Sperm DNA fragmentation index (DFI), motility, binding score, and sperm morphology were measured to evaluate the performance of the MICSI device compared to DGC and DGC plus HA binding.

resultsPractically, the MICSI device was able to select a population of spermatozoa from raw semen with higher progressive motility (p < 0.0001), better morphology (p < 0.0001), and lower DFI (p < 0.0001). When compared to the conventional DGC, the MICSI device produced spermatozoa with significantly higher progressive motility (p < 0.0001) and lower DFI (p < 0.0001). DISCUSSION AND

conclusionThis data show that the MICSI device may offer a clinically applicable alternative for both selecting high-quality sperm for injection into oocytes and providing a platform to do so.

Indexed as

Microfluidic Analytical TechniquesMicrofluidicsOocytesSpermatozoaSperm Injections, IntracytoplasmicCell SeparationDNA FragmentationFemaleHumansHyaluronic AcidMaleSperm MotilityHyaluronic Aciddensity gradient centrifugationhyaluronic acidICSImicrofluidicssperm selection

Identifiers

PMID41718015
PMCPMC13592058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.